JHVEPhoto Inspire Medical Systems ( NYSE: INSP ) and ResMed ( NYSE: RMD ) are both down significantly in Monday trading, apparent casualties of positive data released after the closing bell on June 21 of Eli Lilly's ( LLY ) diabetes and weight loss drug tirzepatide as a sleep apnea treatment. Inspire manufactures an implantable neurostimulation device for obstructive sleep apnea (OSA), while ResMed is a top maker of CPAP (continuous positive airway pressure) machines, considered the gold standard for treatment of OSA. Inspire is off ~18% , while ResMed is down ~12% .
AdaptHealth ( AHCO ), which sells home medical equipment including CPAP machines, is down ~7% . More on Inspire Medical, ResMed Inspire Medical Systems: A Post Q1 Assessment ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug Inspire Medical Systems, Inc. (INSP) Q1 2024 Earnings Call Transcript ResMed Inc.
2024 Q3 - Results - Earnings Call Presentation.